RG7834 is primarily researched for its potential therapeutic applications in treating chronic hepatitis B virus (HBV) infections. It functions by targeting the virus's replication process, specifically inhibiting the expression of viral proteins, which is crucial for the virus's lifecycle. This mechanism helps in reducing the viral load in infected patients. Clinical trials and studies are focused on evaluating its efficacy and safety as part of combination therapies, aiming to improve outcomes for patients with chronic HBV. Its development is significant in the search for more effective treatments that can potentially lead to a functional cure for hepatitis B.